List view / Grid view
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) was devised to create transformative regimens for TB treatment, irrespective of drug resistance status.
Two companies have announced their partnership to work on the 3D printing of tablets for use in clinical trials.
Chemspec Europe, the International Exhibition for Fine and Speciality Chemicals, returns to Cologne for its 35th edition. From 27 – 28 May 2020, renowned manufacturers, suppliers and distributors of fine and speciality chemicals present their latest products, services and research findings to a dedicated audience of industry experts.
A statement by the Takeda reveals the company has acquired PvP as part of a development and option agreement for the drug TAK-062.
NICE has formed a negative opinion for Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine to treat diffuse large B-cell lymphoma.
Researchers have shown that the CALB lipase enzyme can be used to produce macrocycles of a specified shape using biocatalysis.
The FDA and EMA have accepted licence applications for ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS).
The US NIH has initiated a clinical trial for remdesivir and two pharmaceutical companies will work together to manufacture antibody treatments to tackle the coronavirus.
An external review of the medicine Beovu has been announced by Novartis, which produces the drug, according to a new report.
An innovation in drug production methodology could enable manufacturers to use protected boronic acid in reactions, reducing the number of steps required.
Researchers have developed a new mixture of oil and hydrogel that releases drugs in a controlled fashion, preventing overdosing.
A report has revealed that the products in the pipeline to treat dry eye syndrome are expected to expand the number of options available for patients.
The developers of Zejula (niraparib) have announced the FDA will assess the sNDA application under the Real-Time Oncology Review (RTOR) pilot programme.
The generic of ProAir HFA (albuterol sulfate) inhalation aerosol has been approved by the FDA to advance patient access to lower-cost medicines.
A defect in the 2D matrix for the expiration date of diamorphine hydrochloride lyophilisate for solution has been announced by the MHRA.
